Discovery of Novel 2-(2-Benzimidazole)-Substituted Tetrahydrofur-ans as Potent and Selective NaV1.8 Inhibitors for the Treatment of Pain
Journal of Medicinal Chemistry · 08.10.2026 · 69 (19) · 21829-21852
DOI: 10.1021/acs.jmedchem.6c00685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 18.09.2026. Verfasst von Yongqi He und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China. Hauptthemen laut MEDLINE: NAV1.8 Voltage-Gated Sodium Channel, Analgesics, Pain, Benzimidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Youth Innovation Promotion Association of Chinese Academy of Sciences, National Science and Technology Innovation 2030 Major Program, Strategic Priority Program of the Chinese Academy of Sciences.
Abstract (Originalsprache)
Selective inhibition of voltage-gated sodium channel 1.8 (NaV1.8) is a validated non-opioid analgesic strategy. Guided by the well-documented metabolic features of marketed VX-548 in humans and rats, we conducted rational structural optimization to circumvent its major reported metabolic pathways while preserving target potency, which afforded lead compound 31 with nanomolar NaV1.8 potency and favorable subtype selectivity. In male rats, it shows favorable oral bioavailability and >10-fold higher plasma AUC than VX-548, accompanied by potent analgesic efficacy. Favorable and consistent pharmacokinetic profiles are also observed in beagle dogs and cynomolgus monkeys, supporting its balanced cross-species metabolic behavior. Compound 31 also displays a favorable safety profile with no genotoxicity and weak hERG inhibition. Collectively, compound 31 represents a promising metabolically optimized lead for further preclinical evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
- School of Pharmacy, University of Chinese Academy of Sciences, Beijing100049, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing210023, China.
ORCID-Profile: Xin-Yu Leng, Zhaobing Gao, Yushe Yang
Förderung
- Youth Innovation Promotion Association of Chinese Academy of Sciences
- National Science and Technology Innovation 2030 Major Program
- Strategic Priority Program of the Chinese Academy of Sciences
Zitieren
APA
He, Y., Hu, X., Leng, X. Y., Wang, L., Zhan, L., Cai, Y., Chen, X., Gao, Z., Zhang, D., Xu, H., & Yang, Y. (2026). Discovery of Novel 2-(2-Benzimidazole)-Substituted Tetrahydrofur-ans as Potent and Selective NaV1.8 Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry, 69(19), 21829-21852. https://doi.org/10.1021/acs.jmedchem.6c00685
Vancouver
He Y, Hu X, Leng XY, Wang L, Zhan L, Cai Y, et al. Discovery of Novel 2-(2-Benzimidazole)-Substituted Tetrahydrofur-ans as Potent and Selective NaV1.8 Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry. 2026;69(19):21829-21852. doi:10.1021/acs.jmedchem.6c00685
BibTeX
@article{He2026,
author = {He, Yongqi and Hu, Xinyuan and Leng, Xin-Yu and Wang, Linlin and Zhan, Li and Cai, Yongjie and Chen, Xueqin and Gao, Zhaobing and Zhang, Dan and Xu, Haiyan and Yang, Yushe},
title = {Discovery of Novel 2-(2-Benzimidazole)-Substituted Tetrahydrofur-ans as Potent and Selective NaV1.8 Inhibitors for the Treatment of Pain},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {19},
pages = {21829--21852},
doi = {10.1021/acs.jmedchem.6c00685}
}
EUVIMED